AI tools for dentistry

May 6, 2026 · Pouyan Golshani, MD, Interventional Radiologist

Dental AI is moving fast in radiograph interpretation and treatment planning. Here’s the directory. While tools for caries detection and automated cephalometric analysis are grabbing headlines, an equally powerful set of strategic and financial “algorithms” is reshaping the business of dentistry. For practice owners, understanding these is just as critical as adopting the latest clinical tech.

These financial frameworks determine whether you build lasting wealth or leave millions on the table, especially during a practice sale. They govern how you’re taxed, how your practice is valued, and how you can leverage practice assets to accelerate your financial independence. While the physician AI tools directory covers the clinical landscape, this article is your guide to the financial operating system of a modern dental practice. We’ll break down the high-stakes plays that define your career’s financial outcome. For a broader look at this specialty, you can find more dentistry AI tools and resources on the GigHz hub.

Navigating the Private Equity Buyout: Tax Structure is Everything

Most of us get one chance to sell our life’s work. When a private equity (PE) firm comes knocking—a common scenario in dentistry—the headline number they offer is seductive. But the real number, the one that hits your bank account, is determined by the deal structure. The difference between an asset sale and a stock sale can mean a seven-figure swing in your after-tax proceeds.

Here’s the breakdown:

Asset Sale: This is what the PE buyer almost always wants. They get to “step-up” the basis of the assets they buy (chairs, scanners, goodwill) for future depreciation deductions. For you, the seller, it’s often a tax nightmare. The proceeds are allocated to different asset classes. The portion for equipment recapture is taxed as ordinary income. The amount allocated to your accounts receivable is also ordinary income. Only the portion allocated to goodwill gets the favorable long-term capital gains (LTCG) rate. In many deals, this means a huge chunk of your sale price gets taxed at top marginal rates.
Stock Sale: This is what you, the seller, want. You sell the shares of your corporation (your S-corp or C-corp). The entire gain is typically treated as a long-term capital gain, assuming you’ve held the stock for more than a year. This means you pay the much lower LTCG tax rate on the whole deal.

When I look at a deal sheet, the first thing I check isn’t the enterprise value; it’s the sentence that says “this transaction will be treated as an asset sale for tax purposes.” That’s the starting point for negotiation. Your M&A attorney and CPA need to model the after-tax difference between the two structures. Often, you can negotiate a higher purchase price in an asset sale to compensate for your higher tax bill—a “tax gross-up.” Don’t let the buyer’s preference dictate your financial outcome without a fight.

The Trap: The most common mistake is focusing solely on the headline price. A $10M asset sale could easily net you less than a $9M stock sale after taxes. You must model the net, after-tax proceeds. Insist on seeing this calculation from your advisors before you get emotionally committed to a number.

Equity Rollover: Deferring Tax and Staying in the Game

In many PE deals, you won’t get 100% cash at closing. A common structure involves you “rolling over” a portion of your sale proceeds—typically 20-40%—into equity in the new, larger parent company (the “NewCo”). This is a powerful tool, but you have to understand the mechanics.

Here’s how it works: Let’s say your practice is valued at $5 million. The PE firm might offer you $3.5 million in cash and $1.5 million in NewCo equity. That $1.5 million rollover is generally tax-deferred. You don’t owe capital gains tax on that portion until the “second bite of the apple”—when the PE firm sells the entire platform to another, larger buyer, typically 5-7 years down the road. This allows your capital to continue growing in a tax-deferred environment.

The decision of how much to roll over is a personal risk calculation. A larger rollover means more potential upside if the NewCo platform performs well, but it also means more of your net worth is tied to a single, illiquid investment controlled by the PE firm. A smaller rollover gives you more cash to diversify and de-risk your life, but you leave potential gains on the table.

The Trap: Not all rollover equity is created equal. You need to understand its seniority. Are you getting the same class of shares as the PE fund (pari passu), or are you getting subordinated shares that only pay out after the PE fund gets its preferred return? This is a critical diligence point. Another trap is failing to plan for the illiquidity. That rollover money is locked up. You can’t sell it to pay for a kid’s college or buy a vacation home. You need to ensure the cash portion of your deal is sufficient to meet all your life goals for the next 5-7 years.

The Overlooked Goldmine: R&D Tax Credits for Your Practice

When you hear “R&D tax credit,” you probably think of tech companies or pharmaceutical labs. Most dentists have no idea they might qualify. But under Internal Revenue Code §41, many activities common in advanced dental practices are eligible for this lucrative credit, which can be a dollar-for-dollar reduction of your tax liability.

What qualifies? The IRS uses a four-part test, but in simple terms, you’re likely eligible if you’re creating or improving a product, process, or software where there’s technical uncertainty at the outset. In dentistry, this could include:

Developing custom appliances or prosthetics: Experimenting with new materials, digital workflows, or fabrication techniques for complex implant cases, sleep apnea devices, or full-arch restorations.
Creating proprietary clinical software: Building an internal dashboard to track implant integration success rates, developing a custom patient communication sequence, or integrating disparate practice management systems.
Improving clinical processes: Systematically testing and documenting new sterilization protocols, experimenting with different bonding agents to improve longevity, or developing a new digital scanning workflow to reduce chair time.

The credit is generally calculated based on the qualified research expenses (QREs), which include the wages of the people doing the work (you, your associates, your lab techs), the supplies used, and a portion of any contract research. For many practices, this can result in a five- or even six-figure tax credit annually.

The Trap: The biggest trap is simply not knowing the credit exists. The second is poor documentation. You can’t just claim the credit; you have to be able to defend it under audit. This requires contemporaneous documentation of the projects you undertook, the technical challenges you faced, and the expenses you incurred. Work with a specialty tax firm that understands the R&D credit for medical and dental practices. They can help you identify qualifying activities and establish the necessary documentation processes. Most of us just hand our books to a CPA who does a great job on the basics but isn’t a specialist in these complex areas, leaving tens of thousands on the table each year.

Practice Valuation: Speaking the Language of EBITDA Multiples

Whether you plan to sell in two years or twenty, you need to understand what drives your practice’s value. Private equity and corporate buyers don’t value your practice based on gross revenue; they value it based on a multiple of EBITDA—Earnings Before Interest, Taxes, Depreciation, and Amortization. This is a proxy for your practice’s cash flow and profitability.

A typical solo practice might sell for 5-7x EBITDA. A larger group with multiple locations and a strong management team could command a multiple of 10x or higher. Your job as a practice owner is to take actions that increase both your EBITDA and your multiple. Every dollar you add to your annual EBITDA could be worth $7, $8, or even $10 in enterprise value upon sale.

Key drivers that increase your multiple include:

Recurring Revenue: In-house membership plans are a huge value driver. They create predictable, recurring revenue that buyers love, justifying a higher multiple than fee-for-service income.
Provider Concentration: A practice where one dentist generates 80% of the revenue is risky. A practice with 3-4 providers, each contributing 25-30%, is far more stable and valuable.
Scalable Systems: Documented, repeatable processes for marketing, patient intake, billing, and clinical operations show a buyer that the practice can grow without being dependent on the founder.
Modern Facilities and Tech: Up-to-date operatories, CBCT scanners, and digital workflow technology demonstrate a commitment to quality and efficiency, reducing the capital expenditure a new owner will need to invest.

The Trap: A common mistake is “over-personalizing” the practice. If the entire brand, patient flow, and referral network is built around you, the founder, a buyer will see that as a major risk. They will apply a lower multiple because they fear that when you leave, the patients will too. The goal is to build a business that can thrive without you, which paradoxically makes it immensely more valuable when you decide to sell.

Accelerating Wealth with Cost Segregation Studies

If you own the building your practice operates in, or any other commercial or residential rental property, a cost segregation study is one of the most powerful tax strategies available. Most clinicians just hand the purchase documents to their CPA, who then depreciates the entire building over 39 years (for commercial) or 27.5 years (for residential). This is the default, and it’s incredibly inefficient.

A cost segregation study is an engineering-based analysis that dissects the property into its components and reclassifies them into shorter depreciation schedules. Instead of one big 39-year asset, you break it down:

5-Year Property: Carpeting, specialty lighting, decorative millwork, certain plumbing fixtures.
7-Year Property: Office furniture, cabinetry.
15-Year Property: Land improvements like parking lots, landscaping, and sidewalks.
39-Year Property: The structural shell of the building (walls, roof, foundation).

By reclassifying, say, 25% of a $1 million building’s cost from 39-year property to 5- and 15-year property, you can dramatically accelerate your depreciation deductions. This front-loads tax savings, creating massive paper losses in the early years of ownership. Thanks to bonus depreciation rules (though they are phasing down), you can often deduct 100% of the cost of the 5-, 7-, and 15-year property in the very first year.

This strategy becomes even more powerful if your spouse can qualify for Real Estate Professional Status (REPS). If they spend more than 750 hours per year and more than 50% of their working time on real estate activities, your rental losses are no longer “passive.” This means those huge paper losses from cost segregation can be used to offset your active W-2 or 1099 income from practicing dentistry. It’s a common way for high-income clinicians to legally wipe out a significant portion of their income tax liability. You can model out different scenarios using a real estate investing calculator to see the potential impact.

The Trap: Thinking you can do this yourself or that your regular CPA can handle it. A cost segregation study must be performed by a qualified engineering firm to withstand IRS scrutiny. The reports are detailed and technical. It’s a specialized service, but the return on investment is often 50-100x the cost of the study in first-year tax savings.

The world of clinical AI is exciting, but mastering the financial engineering of your practice is what builds true, lasting wealth. These strategies—from structuring a sale to optimizing your taxes—are the tools that give you control over your financial future, allowing you to practice dentistry on your own terms.